Diversified Trust Co Sells 749 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Diversified Trust Co lessened its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 23.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,481 shares of the biopharmaceutical company’s stock after selling 749 shares during the quarter. Diversified Trust Co’s holdings in Alnylam Pharmaceuticals were worth $584,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Geode Capital Management LLC raised its position in shares of Alnylam Pharmaceuticals by 3.2% during the third quarter. Geode Capital Management LLC now owns 2,147,203 shares of the biopharmaceutical company’s stock valued at $589,209,000 after buying an additional 66,928 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in Alnylam Pharmaceuticals by 3.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 487,348 shares of the biopharmaceutical company’s stock valued at $134,035,000 after acquiring an additional 16,756 shares in the last quarter. Avoro Capital Advisors LLC increased its holdings in Alnylam Pharmaceuticals by 33.3% in the 2nd quarter. Avoro Capital Advisors LLC now owns 400,000 shares of the biopharmaceutical company’s stock valued at $97,200,000 after acquiring an additional 100,000 shares during the last quarter. Swiss National Bank lifted its stake in Alnylam Pharmaceuticals by 0.3% in the 3rd quarter. Swiss National Bank now owns 375,400 shares of the biopharmaceutical company’s stock worth $103,246,000 after purchasing an additional 1,000 shares in the last quarter. Finally, Eagle Asset Management Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 25.7% during the 3rd quarter. Eagle Asset Management Inc. now owns 309,589 shares of the biopharmaceutical company’s stock valued at $85,889,000 after purchasing an additional 63,385 shares during the last quarter. 92.97% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Stock Down 1.1 %

NASDAQ:ALNY opened at $237.98 on Friday. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69. Alnylam Pharmaceuticals, Inc. has a 1-year low of $141.98 and a 1-year high of $304.39. The company has a 50-day moving average of $249.60 and a 200 day moving average of $259.41. The firm has a market cap of $30.69 billion, a PE ratio of -90.83 and a beta of 0.34.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The firm had revenue of $500.90 million for the quarter, compared to analysts’ expectations of $532.91 million. The business’s revenue for the quarter was down 33.3% on a year-over-year basis. During the same period in the previous year, the firm earned $1.15 earnings per share. As a group, research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -2.21 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. StockNews.com lowered Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday. Bank of America increased their target price on Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the company a “buy” rating in a research report on Monday, October 14th. HC Wainwright reaffirmed a “buy” rating and set a $400.00 price target on shares of Alnylam Pharmaceuticals in a research note on Monday, November 18th. Cantor Fitzgerald reiterated a “neutral” rating and set a $220.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, October 11th. Finally, Chardan Capital restated a “buy” rating and issued a $300.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, November 1st. One analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $298.61.

Insider Activity

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 5,219 shares of the company’s stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $1,309,864.62. Following the transaction, the chief executive officer now owns 78,880 shares in the company, valued at approximately $19,797,302.40. This represents a 6.21 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CMO Pushkal Garg sold 1,682 shares of the business’s stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $422,148.36. Following the sale, the chief marketing officer now directly owns 17,457 shares in the company, valued at $4,381,357.86. This trade represents a 8.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 10,122 shares of company stock worth $2,540,455. 1.50% of the stock is currently owned by company insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.